Review article: the current treatment of non-cardiac chest pain.

Abstract:

BACKGROUND:Non-cardiac chest pain is one of the most common functional gastrointestinal disorders. By recognising that gastro-oesophageal reflux disease (GERD), oesophageal dysmotility and oesophageal hypersensitivity are the main underlying mechanisms of NCCP, a more directed therapeutic approach has been developed. AIM:To determine the value of the current therapeutic modalities for NCCP. METHODS:Electronic (Pubmed/Medline/Cochrane central) and manual search. RESULTS:Double-dose PPI treatment for two months is a reasonable first choice approach in patients with NCCP because GERD is the most common aetiology. Studies evaluating the role of medical therapy in NCCP patients with hypercontractile oesophageal motility suggest a limited value to muscle relaxants like calcium channel blockers (nifedipine, diltiazem), nitrates and sildenafil. While most trials evaluating pain modulators are small and many are not placebo-controlled, these type of medications appear efficacious in both patients with NCCP due to oesophageal dysmotility and those with functional chest pain. Cognitive behavioural therapy has been extensively studied in patients with functional chest pain with good results. Other psychological techniques such as hypnotherapy, group therapy or coping skills have been scarcely studied but appear to be effective in NCCP patients. CONCLUSION:Medical, endoscopic and surgical therapeutic options are available for the treating physician, although some patients with non-cardiac chest pain may require a multimodal therapeutic approach.

journal_name

Aliment Pharmacol Ther

authors

George N,Abdallah J,Maradey-Romero C,Gerson L,Fass R

doi

10.1111/apt.13458

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

213-39

issue

2

eissn

0269-2813

issn

1365-2036

journal_volume

43

pub_type

杂志文章,评审
  • Review article: clinical evidence to support current therapies of irritable bowel syndrome.

    abstract::This review summarizes the clinical evidence to support current therapies in irritable bowel syndrome (IBS). Fibre is indicated at a dose of at least 12 g per day in patients with constipation-predominant IBS. Loperamide (and probably other opioid agonists) are of proven benefit in diarrhoea-predominant IBS; loperamid...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Camilleri M

    更新日期:1999-05-01 00:00:00

  • A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.

    abstract:BACKGROUND:Sulfasalazine is accepted therapy for active ulcerative colitis, but side-effects and intolerance are common. Balsalazide is an azo-bonded pro-drug which also releases 5-aminosalicylic acid into the colon, but uses an inert carrier molecule. AIM:To compare the safety and efficacy of sul- fasalazine, 3 g, wi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2002.01151.x

    authors: Mansfield JC,Giaffer MH,Cann PA,McKenna D,Thornton PC,Holdsworth CD

    更新日期:2002-01-01 00:00:00

  • The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients.

    abstract:BACKGROUND:Magnetic resonance imaging (MRI) colonography or enterography is increasingly used to assess disease activity and complications in inflammatory bowel disease (IBD). However, no study has evaluated the role of this imaging technique to assess sacroiliitis. AIM:The primary objective was to assess the prevalen...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12680

    authors: Leclerc-Jacob S,Lux G,Rat AC,Laurent V,Blum A,Chary-Valckenaere I,Peyrin-Biroulet L,Loeuille D

    更新日期:2014-05-01 00:00:00

  • Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis.

    abstract:BACKGROUND:The efficacy of many pharmacological agents for preventing post-ERCP pancreatitis (PEP) has been evaluated in randomised controlled trials (RCTs), but it is unclear which agent(s) should be used in clinical practice. Network meta-analyses of RCTs are used to simultaneously compare several agents to determine...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/apt.12534

    authors: Akshintala VS,Hutfless SM,Colantuoni E,Kim KJ,Khashab MA,Li T,Elmunzer BJ,Puhan MA,Sinha A,Kamal A,Lennon AM,Okolo PI,Palakurthy MK,Kalloo AN,Singh VK

    更新日期:2013-12-01 00:00:00

  • An evaluation of near-patient testing for Helicobacter pylori in general practice.

    abstract:INTRODUCTION:A knowledge of Helicobacter pylori status is likely to be important in the management of patients presenting in general practice with dyspepsia. Near-patient testing kits for the detection of the H. pylori antibodies in whole blood, which provide results very quickly, are now available. AIM:To determine t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1997.125296000.x

    authors: Jones R,Phillips I,Felix G,Tait C

    更新日期:1997-02-01 00:00:00

  • Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a double-blind crossover study.

    abstract:BACKGROUND:Abnormal gall-bladder motility has been reported in diabetics. The objective was to evaluate the effect of chronic D2-dopamine receptor inhibition on gall-bladder emptying in diabetic patients. METHODS:Under double-blind placebo-controlled conditions and according to a crossover design, patients were random...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1995.tb00369.x

    authors: Mansi C,Savarino V,Vigneri S,Sciabà L,Perilli D,Mele MR,Celle G

    更新日期:1995-04-01 00:00:00

  • Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.

    abstract:BACKGROUND:Increased risk of cardiovascular and cerebrovascular disease in liver transplant recipients results in particular from the side effects of calcineurin inhibitor-based immunosuppressive therapy. Several studies have demonstrated a more favourable outcome for patients receiving tacrolimus (TAC) as compared wit...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04099.x

    authors: Beckebaum S,Klein C,Varghese J,Sotiropoulos GC,Saner F,Schmitz K,Gerken G,Paul A,Cicinnati VR

    更新日期:2009-10-15 00:00:00

  • Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer.

    abstract:BACKGROUND:Carcinoma of the gall-bladder is the fifth commonest gastrointestinal tract cancer and is endemic in several countries. An association of chronic typhoid carriage and carcinoma of the gall-bladder has been reported. AIM:To clarify whether chronic Salmonella typhi carrier state is associated with carcinoma o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/apt.12655

    authors: Nagaraja V,Eslick GD

    更新日期:2014-04-01 00:00:00

  • Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies.

    abstract:BACKGROUND:In the absence of prior gastrointestinal infection, the risk factors for irritable bowel syndrome (IBS) are not well established. AIM:To identify the incidence and risk factors for IBS in general population samples METHODS: Narrative review of population-based studies. Electronic databases were searched usi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15396

    authors: Creed F

    更新日期:2019-09-01 00:00:00

  • Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.

    abstract:BACKGROUND:Owing to the importance of early treatment, simple and reliable methods for monitoring inflammatory bowel disease (IBD) are needed. AIMS:To determine whether circulating microRNAs are reliable biomarkers for IBD monitoring. METHODS:Serum levels of 17 candidate microRNAs were measured by quantitative real-t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15159

    authors: Chen P,Li Y,Li L,Yu Q,Chao K,Zhou G,Qiu Y,Feng R,Huang S,He Y,Chen B,Chen M,Zeng Z,Zhang S

    更新日期:2019-03-01 00:00:00

  • Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.

    abstract::Alginate-based raft-forming formulations have been marketed word-wide for over 30 years under various brand names, including Gaviscon. They are used for the symptomatic treatment of heartburn and oesophagitis, and appear to act by a unique mechanism which differs from that of traditional antacids. In the presence of g...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00759.x

    authors: Mandel KG,Daggy BP,Brodie DA,Jacoby HI

    更新日期:2000-06-01 00:00:00

  • Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.

    abstract:BACKGROUND:Little data are available regarding the effectiveness and associated microbiome changes of faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in children, especially in those with inflammatory bowel disease (IBD) with presumed underlying dysbiosis. AIM:To investigate C. diffic...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13326

    authors: Hourigan SK,Chen LA,Grigoryan Z,Laroche G,Weidner M,Sears CL,Oliva-Hemker M

    更新日期:2015-09-01 00:00:00

  • Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.

    abstract:BACKGROUND:Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL). AIM:A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2008.03884.x

    authors: Quigley EM,Vandeplassche L,Kerstens R,Ausma J

    更新日期:2009-02-01 00:00:00

  • Review article: safety of bismuth in the treatment of gastrointestinal diseases.

    abstract::Bismuth preparations are commonly used to treat a variety of gastrointestinal disorders, including peptic ulcers and dyspepsia. The safety profile of currently approved bismuth preparations, such as tripotassium dicitrato bismuthate (De-Nol), bismuth subsalicylate (Pepto-Bismol) and ranitidine bismuth citrate (Pylorid...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.1996.22163000.x

    authors: Tillman LA,Drake FM,Dixon JS,Wood JR

    更新日期:1996-08-01 00:00:00

  • Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone.

    abstract:BACKGROUND:Grey Zone (GZ) is an ill-defined situation including patients falling between inactive carrier (IC) state and HBeAg-negative chronic hepatitis B (HBeAg-negative CHB). AIMS:To assess the long-term outcomes of GZ patients compared to IC in the absence of treatment. METHODS:Retrospective analysis of 287 IC an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14613

    authors: Bonacci M,Lens S,Mariño Z,Londoño MC,Rodríguez-Tajes S,Mas A,García-López M,Pérez-Del-Pulgar S,Sánchez-Tapias JM,Forns X

    更新日期:2018-05-01 00:00:00

  • Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.

    abstract:BACKGROUND:Omeprazole has become available in a tablet formulation, a Multiple Unit Pellet System (MUPS) containing a large number of small individually enteric-coated micropellets. AIM:To compare the acid-inhibitory effect of omeprazole MUPS 20 mg with pantoprazole 40 mg and to describe the pharmacokinetics of both d...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00806.x

    authors: Geus WP,Mathôt RA,Mulder PG,Lamers CB

    更新日期:2000-08-01 00:00:00

  • Characterisation of the gastrointestinal mucosa-associated microbiota: a novel technique to prevent cross-contamination during endoscopic procedures.

    abstract:BACKGROUND:The mucosa-associated microbiota appears to be highly relevant to host-microbe interactions in the gastrointestinal (GI) tract. Thus, precise characterisation of the mucosa-associated microbiota may provide important insights for diagnostic and therapeutic development. However, for technical reasons, mucosal...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13622

    authors: Shanahan ER,Zhong L,Talley NJ,Morrison M,Holtmann G

    更新日期:2016-06-01 00:00:00

  • Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

    abstract:BACKGROUND:The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation. AIM:To evaluate biochemical and virological relapse requiring retreatment in noncirrhotic HBeAg-negative CHB in patients who stopped treatment following a period of prolonged...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12908

    authors: Patwardhan VR,Sengupta N,Bonder A,Lau D,Afdhal NH

    更新日期:2014-10-01 00:00:00

  • Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study.

    abstract:BACKGROUND:Peptic ulcer bleeding remains a major healthcare problem despite decreasing prevalence of peptic ulcer disease. The role of chronic obstructive pulmonary disease (COPD) in the risk of peptic ulcer bleeding has not yet been established. AIM:To determine if COPD patients have a higher risk of peptic ulcer ble...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05028.x

    authors: Huang KW,Luo JC,Leu HB,Lin HC,Lee FY,Chan WL,Lin SJ,Chen JW,Chang FY

    更新日期:2012-04-01 00:00:00

  • Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.

    abstract:BACKGROUND:The new tablet formulation of omeprazole (Losec MUPS), is thought to have a stronger acid inhibition than the previously marketed capsules. METHODS:The effects of the proton pump inhibitors lansoprazole and omeprazole tablets on pentagastrin-stimulated acid secretion were compared in Helicobacter pylori-neg...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00823.x

    authors: Müller P,Göksu MA,Fuchs W,Schlüter F,Simon B

    更新日期:2000-09-01 00:00:00

  • Effect of treatment with liu-jun-zi-tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients.

    abstract::The effects of treatment with the Chinese herbal medicine Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms were investigated in 42 patients with chronic idiopathic dyspepsia. By random allocation, 22 patients received oral treatment with 2.5 g TJ-43 three times daily, and 20 patients received ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1993.tb00120.x

    authors: Tatsuta M,Iishi H

    更新日期:1993-08-01 00:00:00

  • Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients.

    abstract:BACKGROUND:Anti-TNFα biologics induce and maintain remission in inflammatory bowel disease (IBD). Also, they have been reported to induce or unmask idiopathic inflammatory demyelinating disease of the central nervous system (IIDD). AIM:To determine if anti-TNFα biologics increased the risk of IIDD in a large cohort of...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12997

    authors: De Felice KM,Novotna M,Enders FT,Faubion WA,Tremaine WJ,Kantarci OH,Raffals LE

    更新日期:2015-01-01 00:00:00

  • Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.

    abstract:BACKGROUND:For patients with UC, flexible maintenance dosing therapy may confer advantages for safety, efficacy, costs and patient preference. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. AIM:To assess the efficacy and safety of tofacitinib dose de-escalation and escalation in patients...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15555

    authors: Sands BE,Armuzzi A,Marshall JK,Lindsay JO,Sandborn WJ,Danese S,Panés J,Bressler B,Colombel JF,Lawendy N,Maller E,Zhang H,Chan G,Salese L,Tsilkos K,Marren A,Su C

    更新日期:2020-01-01 00:00:00

  • Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

    abstract:BACKGROUND:Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02690.x

    authors: Lupascu A,Gabrielli M,Lauritano EC,Scarpellini E,Santoliquido A,Cammarota G,Flore R,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

    更新日期:2005-12-01 00:00:00

  • Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.

    abstract:BACKGROUND:Serum vitamin D levels are associated with bone complications in patients with primary biliary cirrhosis (PBC). Increasing evidence suggests a nonskeletal role of vitamin D in various autoimmune and liver diseases. AIM:To investigate the clinical relevance of vitamin D levels in PBC, especially their associ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13244

    authors: Guo GY,Shi YQ,Wang L,Ren X,Han ZY,Guo CC,Cui LN,Wang JB,Zhu J,Wang N,Zhang J,Cai Y,Han Y,Zhou XM,Fan DM

    更新日期:2015-07-01 00:00:00

  • Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.

    abstract:BACKGROUND:Third-generation cephalosporins (TGC) constitute the empirical first-line therapy for spontaneous bacterial peritonitis (SBP). Hospitalisation, invasive procedures and use of antibiotics may challenge this concept due to an increase in enterococci and other TGC-resistant microorganisms. AIM:To determine pre...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05076.x

    authors: Reuken PA,Pletz MW,Baier M,Pfister W,Stallmach A,Bruns T

    更新日期:2012-05-01 00:00:00

  • Obesity is independently associated with infection in hospitalised patients with end-stage liver disease.

    abstract:BACKGROUND:Infection is the most common cause of mortality in end-stage liver disease (ESLD). The impact of obesity on infection risk in ESLD is not established. AIM:To characterise the impact of obesity on infection risk in ESLD. METHODS:We evaluated the association between infection and obesity in patients with ESL...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13426

    authors: Sundaram V,Kaung A,Rajaram A,Lu SC,Tran TT,Nissen NN,Klein AS,Jalan R,Charlton MR,Jeon CY

    更新日期:2015-12-01 00:00:00

  • Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.

    abstract:BACKGROUND:Pancreatitis is a potentially severe condition. Patients with inflammatory bowel disease (IBD) seem to be at increased risk for acute pancreatitis. AIM:To describe the incidence, main causes and possible predictive factors of acute pancreatitis in inflammatory bowel disease. METHODS:Information was retrosp...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2008.03746.x

    authors: Bermejo F,Lopez-Sanroman A,Taxonera C,Gisbert JP,Pérez-Calle JL,Vera I,Menchén L,Martín-Arranz MD,Opio V,Carneros JA,Van-Domselaar M,Mendoza JL,Luna M,López P,Calvo M,Algaba A

    更新日期:2008-09-01 00:00:00

  • Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.

    abstract:BACKGROUND:Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear. AIM:To study the degree of on-treatment viral anti...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16172

    authors: Brakenhoff SM,de Man RA,Boonstra A,van Campenhout MJH,de Knegt RJ,van Bömmel F,van der Eijk AA,Berg T,Hansen BE,Janssen HLA,Sonneveld MJ

    更新日期:2021-01-01 00:00:00

  • Effectiveness and safety of obeticholic acid in a Southern European multicenter cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.

    abstract:BACKGROUND:Obeticholic acid (OCA) was recently approved as the only on-label alternative for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to ursodeoxycholic acid (UDCA). However, few data are available outside clinical trials. AIM:To assess the effectiveness and safety of OCA...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16181

    authors: Gomez E,Garcia Buey L,Molina E,Casado M,Conde I,Berenguer M,Jorquera F,Simón MA,Olveira A,Hernández-Guerra M,Mesquita M,Presa J,Costa-Moreira P,Macedo G,Arenas JI,Manuel Sousa J,Ampuero J,Morillas RM,Santos A,De Car

    更新日期:2020-12-12 00:00:00